Literature DB >> 15621384

Central neuropathic itch from spinal-cord cavernous hemangioma: a human case, a possible animal model, and hypotheses about pathogenesis.

Dennis Daniel Dey1, Orlando Landrum, Anne Louise Oaklander.   

Abstract

Cavernous hemangiomas (cavernomas) of the spinal cord are rare congenital malformations that comprise less than 5% of all intramedullary lesions. Despite this rarity, we describe the third case of central neuropathic itch associated with intramedullary cavernoma. Since fewer than 10 cases of central spinal itch from all causes have been published, this concurrence suggests the possibility of a specific association. A middle-aged man developed chronic disabling neuropathic itch and pain affecting his left shoulder and arm after frank hemorrhage of a midcervical cavernoma. We hypothesize that the relatively rostro-dorsal location of his lesion increased its likelihood of causing itch as well as pain. The microscopic pathology of cavernomas, specifically their gliotic rim containing hemosiderin-laden phagocytes, fosters ectopic firing of nearby neurons and makes cranial cavernomas highly epileptogenic. We hypothesize that these pathological features predispose cavernomas to cause central itch if they are located near, but spare, the central itch projection neurons in lamina I of the dorsal horn. Quisqualate injections into the deeper layers (neck) of the dorsal horns of rats produce pathologically similar lesions. Such rats develop unilateral dermatomal hyperalgesia and self-injurious scratching and biting (autotomy). Although this pathological grooming is currently interpreted as a response to chronic pain, we propose that it more likely models scratching provoked by central neuropathic itch, as seen in our patient and others. Study of quisqualate-injected rats may provide leads towards new treatments for neuropathic itch.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621384     DOI: 10.1016/j.pain.2004.09.032

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  14 in total

1.  7T MRI of spinal cord injury.

Authors:  Julien Cohen-Adad; Wei Zhao; Lawrence L Wald; Anne Louise Oaklander
Journal:  Neurology       Date:  2012-11-27       Impact factor: 9.910

Review 2.  Neuropathic itch.

Authors:  Anne Louise Oaklander
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 3.  Management of itch in atopic dermatitis.

Authors:  Judith Hong; Joerg Buddenkotte; Timothy G Berger; Martin Steinhoff
Journal:  Semin Cutan Med Surg       Date:  2011-06

4.  Bilateral transient changes in thalamic nucleus ventroposterior lateralis after thoracic hemisection in the rat.

Authors:  Li Liang; Lorne M Mendell
Journal:  J Neurophysiol       Date:  2013-06-05       Impact factor: 2.714

5.  Effects of distal nerve injuries on dorsal-horn neurons and glia: relationships between lesion size and mechanical hyperalgesia.

Authors:  J W Lee; S M Siegel; A L Oaklander
Journal:  Neuroscience       Date:  2008-10-11       Impact factor: 3.590

6.  Intractable pruritus after traumatic spinal cord injury.

Authors:  Deborah A Crane; Kenneth M Jaffee; Anjana Kundu
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

7.  Dermatomal scratching after intramedullary quisqualate injection: correlation with cutaneous denervation.

Authors:  Kori L Brewer; Jeung Woon Lee; Heather Downs; Anne Louise Oaklander; Robert P Yezierski
Journal:  J Pain       Date:  2008-07-10       Impact factor: 5.820

Review 8.  Itch and neuropathic itch.

Authors:  Junichi Hachisuka; Michael C Chiang; Sarah E Ross
Journal:  Pain       Date:  2018-03       Impact factor: 6.961

Review 9.  Why we scratch an itch: the molecules, cells and circuits of itch.

Authors:  Diana M Bautista; Sarah R Wilson; Mark A Hoon
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

Review 10.  New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?

Authors:  Tong Liu; Ru-Rong Ji
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.